BRAF codon(s) 600 any
Presence of a BRAF c.1799T>A, p.Val600Glu (V600E) mutation in a microsatellite unstable colorectal carcinoma indicates that the tumor is probably sporadic and not associated with Lynch syndrome (HNPCC). However, if a BRAF mutation is not detected, the tumor may either be sporadic or Lynch syndrome associated. Detection of BRAF mutations may also be useful in determining patient eligibility for anti-EGFR treatment. Approximately 8–15% of colorectal cancer (CRC) tumors harbor BRAF mutations. The presence of BRAF mutation is significantly associated with right-sided colon cancers and is associated with decreased overall survival. Some studies have reported that patients with metastatic CRC (mCRC) that harbor BRAF mutations do not respond to anti-EGFR antibody agents cetuximab or panitumumab in the chemotherapy-refractory setting. BRAF V600-mutated CRCs may not be sensitive to V600E targeted TKIs
Davies, H., Bignell, G. R., et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417, 949-954.
Di Nicolantonio, F., et al. Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer. J Clin. Oncol. (2008) 26, 5705-5712.
Maestro, M.L. et al. Role of the BRAF Mutations in the Microsatellite Instability Genetic Pathway in Sporadic Colorectal Cancer.Ann. Surg. Oncol. (2007) 14, 1229–1236.
Tol, J. et al. BRAF Mutation in Metastatic Colorectal Cancer. N. Engl. J. Med. (2009) 361, 98-99.
Sharma, S.G., and M.L. Gulley. BRAF mutation testing in colorectal cancer. Arch. Pathol. Lab. Med. (2010) 134, 1225-1228
Prahallad et al.. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.Nature. 2012 Jan 26;483(7387):100-3.
Gravalos C et al.. Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26.
Disclaimer: You assume full responsibility for all risks associated with using this PMKB website. The IPM makes no guarantee of the comprehensiveness, reliability or accuracy of the information on this website and the IPM assumes no responsibility for errors in the information associated with this web site. Healthcare providers and patients must integrate all clinical and laboratory findings as well as information from a variety of sources before deciding on appropriate clinical care options.